The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Immune modulation and dysregulation in MDS and AML

Featured
Sep 24, 2020
Share:

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the AML Hub was delighted to speak to Steering Committee Member Naval Daver, MD Anderson Cancer Center, Houston, US, about immune modulation and dysregulation in MDS and AML.

Immune modulation and dysregulation in MDS and AML

Immune therapy has emerged as a major treatment approach to both solid tumors and hematological malignancies over the past 15 years, but is less advanced in the MDS/AML setting. Here, Naval Daver highlights the novel targets and therapeutic agents that are being used to modulate immune responses and address immune dysregulation in MDS and AML.

Share:
More about...

Your opinion matters

Which talk topic are you most looking forward to at ASH?
1 vote - 2 days left ...

Newsletter

Subscribe to get the best content related to AML delivered to your inbox